Latest On Innate Pharma S.A (IPHA):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-04-11 08:17 EST | News | Innate Pharma: Exciting Company But Poor Stock In The U.S. | N/A |  |
| 2023-04-03 15:47 EST | News | Innate stock surges ~15% after license deal with Takeda | N/A | |
| 2023-03-23 13:19 EST | News | Innate Pharma GAAP EPS of -€0.73, revenue of €57.67M | N/A | |
| 2023-01-25 12:24 EST | News | Innate, Sanofi licensing deal gets US antitrust clearance | N/A | |
| 2022-12-19 13:04 EST | News | Sanofi and Innate Pharma join hands for NK cell therapeutics in oncology | N/A | |
About Innate Pharma S.A (IPHA):
Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell read more... engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.
General
- Name Innate Pharma S.A
- Symbol IPHA
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 247
- Fiscal Year EndDecember
- IPO Date2019-10-17
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://www.innate-pharma.com
Valuation
- Trailing PE 13.66
- Price/Sales (Trailing 12 Mt.) 5.74
- Price/Book (Most Recent Quarter) 1.39
- Enterprise Value Revenue 4.28
- Enterprise Value EBITDA 8.5
Financials
- Most Recent Quarter 2020-06-30
- Profit Margin -70%
- Return on Assets -8%
- Return on Equity -23%
- Revenue Per Share $0
- Gross Profit 6.97 million
- Quarterly Earnings Growth -37.9%
Highlights
- Market Capitalization 359.95 million
- Analyst Target Price $6.58
Share Statistics
- Shares Outstanding 78.97 million
- Shares Float 51.08 million
- % Held by Insiders 155%
- % Held by Institutions 2.27%
- Shares Short 4853
- Shares Short Prior Month 6773
- Short Ratio 0.07
Technicals
- Beta 0.22
- 52 Week High $8.23
- 52 Week Low $3.55
- 50 Day Moving Average 4.44
- 200 Day Moving Average 4.47
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Innate Pharma S.A (IPHA) Dividend Calendar:
Innate Pharma S.A (IPHA) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Innate Pharma S.A (IPHA) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Innate Pharma S.A (IPHA) Chart:
Innate Pharma S.A (IPHA) News:
Below you will find a list of latest news for Innate Pharma S.A (IPHA) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Innate Pharma S.A (IPHA) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest IPHA Trades:
Innate Pharma S.A (IPHA) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-10-23 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-10-13 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-09-08 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-08-12 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-08-11 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-07-29 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-07-16 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-06-24 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-06-24 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-05-20 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-05-14 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-05-12 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-05-06 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-04-28 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-04-24 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-04-24 | 20-F (Annual and transition report of foreign private issuers [Sections 13 or 15(d)]) | |
| 2020-04-17 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-04-14 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-04-14 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |